{"name":"Windgap Medical","slug":"windgap","ticker":"PRIVATE","exchange":"Private","domain":"windgapmedical.com","description":"Windgap Medical is a private company focused on developing innovative drug delivery solutions for the treatment of allergies. Their key products include the Windgap Medical's proprietary drug delivery system, which has shown promise in improving the efficacy and safety of allergy treatments. As a private company, Windgap Medical does not publicly disclose detailed financial information, but they have received significant funding from investors to support their research and development efforts. Windgap Medical's market position is strong, with a growing pipeline of products in development.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"John Lopes","sector":"MedTech / Drug Delivery / Allergy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~$80M valuation)","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"deal","headline":"Windgap Medical Raises $20 Million in Series B Funding","summary":"Windgap Medical announced the completion of a $20 million Series B funding round, led by new investor, Sofinnova Partners.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"Windgap Medical Receives FDA Clearance for Its Proprietary Drug Delivery System","summary":"Windgap Medical announced that it has received FDA clearance for its proprietary drug delivery system, which is designed to improve the efficacy and safety of allergy treatments.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxQVWpUaklMaHpGRTRyakNSSi14eUUxUGd1MnUxWk1fWkIta3ZhYmRsTk4wbEs0UzFrQXJhbHA2VU1oc3NuNDBleVVPMEFfUGo4REV0clplczA4UXhkN1RWalBUTm8xNnhWSlFOWXB5NnhLMUtXbXdNajFKR25jcDFTS3Vlb3hIeEk4NWJqU3Jib2pWeVdicGVpazFqNmJxMEZDbnE2OTVNQmFyeXphSDl2dWM4V2NQWTg5V0Vuc1RHQ3RydVh3TkdOaDVleWVXSTRnVi1od0JGdzJERzN2WjhiUTFtWTYzdFRCbTJSclN0bExXcTVHMVRxellmckVmMHE5Zm9kT1pvaFVyZzdTMmZOV2s5QXhpN0FsSjdqem9QcnpSRzVuNlBZ?oc=5","date":"2021-09-07","type":"pipeline","source":"PR Newswire","summary":"Taiwania Capital Joins Pool of Existing Investors to Fund $17 Million of Series B-1 Investment in Novel Drug Delivery Company, Windgap Medical, Inc. - PR Newswire","headline":"Taiwania Capital Joins Pool of Existing Investors to Fund $17 Million of Series B-1 Investment in Novel Drug Delivery Co","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Sanofi","GlaxoSmithKline"],"therapeuticFocus":["Allergy Treatment"],"financials":null,"yahoo":null}